VAERS 2669520
MERCK & CO. INC. · MEASLES + MUMPS + RUBELLA (MMR II) · Charge U025199
- Staat
- OH
- Alter
- -
- Geschlecht
- F
- Eingang
- 10.08.2023
- Impfdatum
- -
- Beginn
- 28.04.2023
- Tage bis Beginn
- -
- Dosis
- 3
- Route/Site
- OT / LA
Symptomtext
Side effects/anaphylaxis; This spontaneous report was received from a nurse and refers to an unspecified patient. Information regarding the patient's concurrent conditions, medical history, historical drugs and concomitant therapies was not provided. On an unknown date, the patient was vaccinated with with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) injection, albumin status rHA lot #U025199, expiration date not reported but upon internal validation established as 13-AUG-2023, administered for prophylaxis (strength, and route of administration were not provided). On an unknown date, the patient experienced side effects. At the time of reporting, the outcome of the side effects was not known. The causal relationship between side effects and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) was unknown. This is a non-valid case due to lack of patient's identifiers. Follow-up was received from a consumer on 03-AUG-2023 referring to the 21-year-old female patient. The patient had no pertinent medical history, drug reactions/allergies, concurrent conditions or concomitant medications (reported as "none"). She was not ill at the time of vaccination. On an unknown date, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) subcutaneously, in the left deltoid, corresponding to the third dose of the vaccine. Additionally, the patient was also vaccinated with an unspecified varicella vaccine (manufacturer unknown) (reported as "varicella") lot # reported as "W006413" with expiration date reported as "23-FEB-2024", subcutaneously in the left arm, for prophylaxis (strength and dose were not provided). The vaccines were administered as private doctor's office/hospital. On 28-APR-2023, the patient experienced anaphylaxis. The patient's mother took her to the emergency room (ER) and a allergy testing was done (results not provided). She required X-ray (result not provided) and was treated with intravenous medications and with epinephrine, methylprednisolone sodium succinate (SOLUMEDROL), famotidine (PEPCID) and ammonium chloride (+) diphenhydramine hydrochloride (BENADRYL). She also received oral antihistamines and steroids at home. The patient responded to treatment and recovered from the event on 27-JUN-2023. The rechallenge and rechallenge results were reported as positive for the suspect vaccines. The reporter considered the event to be related to the suspect vaccines. The reporter considered anaphylaxis to be a life-threatening event and also a medically significant event. Follow-up information provided patient's identifiers, therefore, the case was considered as a valid case.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Anaphylactic reaction
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -